

Application No. 10/076,071  
Amendment dated September 7, 2005  
Reply to Office Action mailed April 8, 2005

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-530 (Canceled).

531. (Currently amended) A method of treating an angiogenic disease or condition in an animal comprising administering to the animal an effective amount of a metal-binding peptide which does not have a metal ion bound to it the sequence of the peptide being:

$P_1 - P_2$ ,

wherein:

$P_1$  is:

Xaa<sub>1</sub> Xaa<sub>2</sub> His or

Xaa<sub>1</sub> Xaa<sub>2</sub> His Xaa<sub>3</sub>,

the  $P_1$  portion of the peptide being linear;

$P_2$  is (Xaa<sub>4</sub>)<sub>n</sub>;

Xaa<sub>1</sub> is the N-terminal amino acid of the peptide, the only substituents on the  $\alpha$ -amino group of Xaa<sub>1</sub> are hydrogen ~~has an unsubstituted  $\alpha$ -amino group~~, and Xaa<sub>1</sub> is glycine, alanine, valine, leucine, isoleucine, serine, threonine, aspartic acid, asparagine, glutamic acid, glutamine, lysine, hydroxylysine, histidine, arginine, ornithine, phenylalanine, tyrosine, tryptophan, cysteine, methionine, or  $\alpha$ -hydroxymethylserine;

Xaa<sub>2</sub> is glycine, alanine,  $\beta$ -alanine, valine, leucine, isoleucine, serine, threonine, aspartic acid, asparagine, glutamic acid, glutamine, lysine, hydroxylysine, histidine, arginine, ornithine, phenylalanine, tyrosine, tryptophan, cysteine, methionine, or  $\alpha$ -hydroxymethylserine;

Xaa<sub>3</sub> is glycine, alanine, valine, lysine, arginine, ornithine, aspartic acid, glutamic acid, asparagine, glutamine or tryptophan;

Xaa<sub>4</sub> is any amino acid; and

n is 0-100;

or a physiologically-acceptable salt thereof.